is retatrutide on the market for weight loss: Study shows 30% body weight loss ESC 2024: Retatrutide improves lipid

While lean muscle typically accounts for 25% of the total mass lost during a weight management diet or following bariatric surgery, use of AOM may increase this percentage up to 40% 3,4,5

doi: 10.1177/25424823251388650

In perfused pancreas models, it has been observed that GLP-1 significantly inhibits glucagon secretion from pancreatic -cells across various glucose levels

Another myth is that sublingual delivery is less effective than injections

Companion Supplies & Routine Support How I Researched This Comparison I have spent the last two years building research infrastructure for this exact question

Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist licensed in the UK for glycaemic control and, under the brand Zepbound, for chronic weight management